Story
Novo Nordisk Sues Eli Lilly, Alleging False Advertising for Weight-Loss Drugs
Summary
Novo Nordisk has filed a federal lawsuit against rival Eli Lilly, claiming its ads for weight-loss drugs Zepbound and Mounjaro make false and misleading comparisons to Novo's Wegovy and Ozempic. The suit escalates the corporate battle in the lucrative obesity treatment market.
Novo Nordisk has filed a lawsuit against its primary competitor, Eli Lilly, alleging the U.S. drugmaker is using false and misleading advertising to promote its popular weight-loss and diabetes drugs. The suit, filed in a U.S. federal court, escalates the intense rivalry between the two pharmaceutical giants in the multi-billion dollar obesity drug market.
Details of the Lawsuit
The complaint, filed on Tuesday in the U.S. District Court in New Jersey, claims that Eli Lilly's nationwide advertising campaigns for Zepbound and Mounjaro violate federal and state laws, including the Lanham Act, which governs false advertising and unfair competition.
Novo Nordisk alleges that Lilly's advertisements create a deceptive impression of superior efficacy. The core of the claim is that Lilly compares the highest approved doses of its medications against lower, less effective doses of Novo's competing drugs, Wegovy and Ozempic, while omitting data from Novo's newer, higher-dose options.
A Battle Over Dosing and Data
According to Novo's general counsel, John Kuckelman, Lilly's ads compare weight-loss results of approximately 50 pounds for Zepbound with about 33 pounds for Wegovy. Novo argues this is an unfair comparison.
AdKuckelman stated that separate late-stage trials of the highest approved doses of each drug showed much more comparable results: an average weight loss of about 48 pounds for Zepbound and 47 pounds for Wegovy. The lawsuit emphasizes that no head-to-head clinical trial has directly compared the highest doses of the two medicines.
Legal Demands and Market Context
The Danish pharmaceutical company is seeking a court order that would require Lilly to withdraw the advertisements and fund a corrective ad campaign. Novo Nordisk also stated it plans to seek a preliminary injunction if Lilly does not voluntarily comply.
This legal action follows a cease-and-desist letter Novo sent to Lilly in April, after the U.S. approval of a higher 7.2-milligram dose of Wegovy. According to the complaint, Lilly did not formally respond but instead added a disclaimer to its ads that Novo's counsel described as "inadequate." The lawsuit marks a significant new front in the fierce competition for dominance in the rapidly expanding market for GLP-1 therapies.
Read next
More on Stocks
Morgan Stanley Names Baker Hughes Top Energy Services Pick, Citing Growth and Synergies
The investment bank set a $70 price target for Baker Hughes (NASDAQ: BKR), highlighting the successful integration of Chart Industries and a projected 3-4x revenue growth in its power business by 2029.
CD&R and Warburg Pincus in Advanced Talks for Canaccord's UK Wealth Arm, Sources Say
Private equity giants Clayton, Dubilier & Rice and Warburg Pincus are reportedly the leading bidders in a joint effort to acquire Canaccord Genuity's UK wealth division. The deal, part of a wider consolidation trend, could value the unit at over £1 billion.
Apple Reportedly Developing Screenless Fitness Tracker to Compete With Whoop
Apple is in the early stages of exploring a screenless, wrist-worn health tracker, a move that would expand its wearables portfolio and place it in direct competition with specialized devices from companies like Whoop, according to a Bloomberg report.
Anthropic Launches Claude Opus 5.5, Cutting Price for High-End AI Model
The AI startup has released its newest model, Claude Opus 5.5, which it says offers performance comparable to its top-tier system at a significantly lower cost, escalating competition in the artificial intelligence market.